Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PRQR 
ProQR Therapeutics BV (PRQR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/15/2025: PRQR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8.88
1 Year Target Price $8.88
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -52.01% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 215.96M USD | Price to earnings Ratio - | 1Y Target Price 8.88 |
Price to earnings Ratio - | 1Y Target Price 8.88 | ||
Volume (30-day avg) 8 | Beta 0.43 | 52 Weeks Range 1.07 - 4.62 | Updated Date 08/16/2025 |
52 Weeks Range 1.07 - 4.62 | Updated Date 08/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.47 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.0795 | Actual -0.12 |
Profitability
Profit Margin -231.45% | Operating Margin (TTM) -308.15% |
Management Effectiveness
Return on Assets (TTM) -20.47% | Return on Equity (TTM) -79.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 96073298 | Price to Sales(TTM) 12.6 |
Enterprise Value 96073298 | Price to Sales(TTM) 12.6 | ||
Enterprise Value to Revenue 5 | Enterprise Value to EBITDA -2.1 | Shares Outstanding 105344000 | Shares Floating 66030705 |
Shares Outstanding 105344000 | Shares Floating 66030705 | ||
Percent Insiders 18.04 | Percent Institutions 48.47 |
Upturn AI SWOT
ProQR Therapeutics BV
Company Overview
History and Background
ProQR Therapeutics BV, founded in 2012, focused on developing RNA therapies for rare genetic eye diseases. Their primary focus was on addressing unmet needs in inherited retinal diseases.
Core Business Areas
- RNA Therapeutics Development: Focused on developing RNA-based therapies targeting genetic mutations causing rare eye diseases.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their therapeutic candidates.
- Research and Development: Investing in research to discover and develop new RNA therapies.
Leadership and Structure
Details of ProQR's leadership team and structure are difficult to verify as the company has faced financial difficulties and restructuring. Historically, the structure included a CEO, CMO, CFO, and other executive leadership positions overseeing R&D, clinical development, and commercial operations. The organizational structure was typical for a biotech company focused on drug development.
Top Products and Market Share
Key Offerings
- Sepofarsen: Sepofarsen (QR-110) was their lead investigational drug for Leber congenital amaurosis 10 (LCA10) caused by the p.Cys998X mutation in the *CEP290* gene. Market share unavailable as it was not approved for commercial sale. Competitors include companies developing gene therapies for LCA, such as Editas Medicine (EDIT), though they target different mutations.
- Atuparsen: Atuparsen (QR-421a) was a therapy targeting Usher syndrome type 2A caused by mutations in the *USH2A* gene. Market share unavailable as it was not approved for commercial sale. Competitors include companies developing gene therapies for Usher syndrome.
Market Dynamics
Industry Overview
The biopharmaceutical industry, specifically the segment focused on RNA therapeutics, is characterized by high innovation, significant investment in research and development, and a complex regulatory landscape. The market is driven by the increasing understanding of genetic diseases and the potential of RNA-based therapies to address previously untreatable conditions.
Positioning
ProQR aimed to be a leader in RNA therapeutics for rare eye diseases. Their competitive advantage was their focus on a specific technology platform and a pipeline of product candidates targeting well-defined genetic mutations.
Total Addressable Market (TAM)
The TAM for inherited retinal diseases is estimated to be in the billions of dollars. ProQR's positioning was focused on specific genetic mutations within this broader market, giving them a portion of this large TAM.
Upturn SWOT Analysis
Strengths
- Focused pipeline of RNA-based therapies
- Expertise in RNA technology
- Focus on rare genetic eye diseases with high unmet need
Weaknesses
- High cash burn rate
- Clinical trial risks and uncertainties
- Dependence on successful clinical trial outcomes
- Financial difficulties and restructuring
Opportunities
- Potential for breakthrough therapies in rare eye diseases
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through new drug targets
Threats
- Competition from other companies developing gene therapies and RNA therapeutics
- Regulatory hurdles and delays
- Clinical trial failures
- Funding constraints and economic downturns
Competitors and Market Share
Key Competitors
- EDIT
- SPHR
Competitive Landscape
ProQR faced intense competition from companies with more advanced or diverse pipelines and greater financial resources. Their success depended on the successful development and commercialization of their lead product candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth was characterized by increasing R&D investment and fluctuating collaboration revenue. The company faced significant setbacks due to clinical trial failures and financial challenges.
Future Projections: Future projections are uncertain due to ProQR's current financial difficulties. Analyst estimates are unavailable at this time.
Recent Initiatives: Recent initiatives have likely focused on cost reduction and restructuring to address financial challenges.
Summary
ProQR Therapeutics faced significant challenges in developing and commercializing its RNA-based therapies. Clinical trial setbacks and financial constraints have negatively impacted the company's prospects. While the company's focused pipeline and expertise in RNA technology were strengths, overcoming these challenges proved difficult. ProQR needs to address its financial sustainability and navigate a competitive landscape to secure its future. It remains unclear if it can overcome the problems.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (historical)
- Analyst reports (historical)
- Press releases (historical)
- Industry news and publications
Disclaimers:
The information provided is based on available data and analysis. The biopharmaceutical industry is highly dynamic, and future performance is subject to risks and uncertainties. The company's current situation and future are uncertain.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ProQR Therapeutics BV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2014-09-18 | Founder, CEO & Member of Management Board Mr. Daniel Anton de Boer | ||
Sector Healthcare | Industry Biotechnology | Full time employees 166 | Website https://www.proqr.com |
Full time employees 166 | Website https://www.proqr.com | ||
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for metabolic dysfunction-associated steatohepatitis (MASH) targeting patatin-like phospholipase domain-containing protein 3 (PNPLA3); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as additional programs in Rett Syndrome, additional CNS programs, and multiple other unnamed targets and programs. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.